Breaking News

Halifax To Acquire Envision Pharma

June 18, 2013

Adds compliance-driven technology and services

The Halifax Group has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is a global technology and scientific communication company focused on the pharma, biopharma and medical device industries. Halifax partnered with management to provide a significant equity investment. Financial terms were not disclosed.
Envision offers solutions including strategic publication planning and related data dissemination and consultancy services, along with technology solutions. Envision Pharma has two offices in the UK and three in the U.S. in Philadelphia, PA, Southport, CT, and Glastonbury, CT. The company has approximately 280 employees.
Envision's chief executive officer, Brian Hepburn, said, "Thanks to the hard work of our employees and enduring commitment of our customers, we successfully navigated our sale process and are excited to begin our next phase of growth in partnership with the Halifax team. Halifax's proven expertise in pharma and health services made them the ideal partner of choice for our company, and their involvement will enable us to invest in several new innovative platforms and related services to further support the evolving needs of our clients."
"Envision provides industry-leading technology and services to many of the world's foremost pharmaceutical and medical technology companies," said David Dupree, managing director at Halifax. "These compliance-driven services are critical to the pharmaceutical development and commercialization process, and we believe the company is well-positioned to build on its 12-year track record of success."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks